Literature DB >> 9143686

The genetic defect in ataxia-telangiectasia.

M F Lavin1, Y Shiloh.   

Abstract

The autosomal recessive human disorder ataxia-telangiectasia (A-T) was first described as a separate disease entity 40 years ago. It is a multisystem disease characterized by progressive cerebellar ataxia, oculocutaneous telangiectasia, radiosensitivity, predisposition to lymphoid malignancies and immunodeficiency, with defects in both cellular and humoral immunity. The pleiotropic nature of the clinical and cellular phenotype suggests that the gene product involved is important in maintaining stability of the genome but also plays a more general role in signal transduction. The chromosomal instability and radiosensitivity so characteristic of this disease appear to be related to defective activation of cell cycle checkpoints. Greater insight into the nature of the defect in A-T has been provided by the recent identification, by positional cloning, of the responsible gene, ATM. The ATM gene is related to a family of genes involved in cellular responses to DNA damage and/or cell cycle control. These genes encode large proteins containing a phosphatidylinositol 3-kinase domain, some of which have protein kinase activity. The mutations causing A-T completely inactivate or eliminate the ATM protein. This protein has been detected and localized to different subcellular compartments.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9143686     DOI: 10.1146/annurev.immunol.15.1.177

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  167 in total

1.  p53 down-regulates CHK1 through p21 and the retinoblastoma protein.

Authors:  V Gottifredi; O Karni-Schmidt; S S Shieh; C Prives
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

2.  Purification and DNA binding properties of the ataxia-telangiectasia gene product ATM.

Authors:  G C Smith; R B Cary; N D Lakin; B C Hann; S H Teo; D J Chen; S P Jackson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

3.  mus304 encodes a novel DNA damage checkpoint protein required during Drosophila development.

Authors:  M H Brodsky; J J Sekelsky; G Tsang; R S Hawley; G M Rubin
Journal:  Genes Dev       Date:  2000-03-15       Impact factor: 11.361

4.  ATM protein synthesis patterns in sporadic breast cancer.

Authors:  R Kairouz; R A Clarke; P J Marr; D Watters; M F Lavin; J H Kearsley; C S Lee
Journal:  Mol Pathol       Date:  1999-10

Review 5.  Reverse genetic studies of homologous DNA recombination using the chicken B-lymphocyte line, DT40.

Authors:  E Sonoda; C Morrison; Y M Yamashita; M Takata; S Takeda
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-01-29       Impact factor: 6.237

6.  Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation.

Authors:  B Xu; M B Kastan
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

7.  Targeted inhibition of ATR or CHEK1 reverses radioresistance in oral squamous cell carcinoma cells with distal chromosome arm 11q loss.

Authors:  Madhav Sankunny; Rahul A Parikh; Dale W Lewis; William E Gooding; William S Saunders; Susanne M Gollin
Journal:  Genes Chromosomes Cancer       Date:  2013-11-25       Impact factor: 5.006

8.  Integrated signaling in developing lymphocytes: the role of DNA damage responses.

Authors:  Jeffrey J Bednarski; Barry P Sleckman
Journal:  Cell Cycle       Date:  2012-10-03       Impact factor: 4.534

Review 9.  Warts and all: human papillomavirus in primary immunodeficiencies.

Authors:  Jennifer W Leiding; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

10.  Ionizing radiation induces ataxia telangiectasia mutated kinase (ATM)-mediated phosphorylation of LKB1/STK11 at Thr-366.

Authors:  Gopal P Sapkota; Maria Deak; Agnieszka Kieloch; Nick Morrice; Aaron A Goodarzi; Carl Smythe; Yosef Shiloh; Susan P Lees-Miller; Dario R Alessi
Journal:  Biochem J       Date:  2002-12-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.